Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults

27 mai 2026 mis à jour par: Keipp Talbot, Vanderbilt University
Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

In the United States, yearly influenza vaccination begins in August or September. However, influenza season can extend into April of the following year. The duration of protection from annual vaccination in older adults is unknown, and little is known about factors associated with the maintenance of response throughout the influenza season. This study evaluated factors associated with the immune response of older adults to trivalent influenza vaccine and the maintenance of antibody responses for the duration of the influenza season.

Subjects

Subjects were enrolled at two sites, Vanderbilt University Medical Center (Nashville, TN) and Marshfield Clinic Research Foundation (Marshfield, WI), during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no contraindication to influenza vaccination. Subject recruitment included advertisements at Vanderbilt University Medical Center and letters of invitation to older adults who had received an influenza vaccine in the year prior at Marshfield Clinic.1 All subjects were vaccinated either by their usual caregiver or by the study staff. Strain components for the 2009-2010 Northern Hemisphere vaccine included A/Brisbane/59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2), and B/Brisbane/60/2008-like. Participants were given the trivalent seasonal vaccine because the 2009 H1N1 pandemic vaccine was not available.

Data Collection

All subjects donated serum pre-vaccination (S1) during September through October 2009, 21 - 28 days post-vaccination (S2) and post-influenza season, May through July, 2010, approximately 250 days (8 months) post-vaccination (S3). Study procedures, informed consent documents and data collection forms were reviewed and approved by Institutional Review Boards at each of the study sites.

Age, co-morbid conditions, sex, and race were ascertained from participant interview. Recent chemotherapy, radiation therapy, or use of immunomodulating medications were ascertained by self-report or chart review. CDC-defined high risk medical conditions were identified by self-report of organ transplantation, cancer, diabetes mellitus, splenectomy (functional or anatomic), cardiovascular disease, renal disease, sickle cell disease, chronic pulmonary disease, seizure disorder, immune deficiency, or dementia.2 Self-reported stress was determined by asking participants to respond yes or no to the question "Have you suffered psychological stress or acute disease in the past 3 months?" included as part of the Mini Nutritional Assessment Questionnaire.3 Height and weight were measured by research study staff and body mass index (BMI) was calculated as weight (kg) / height (m)2.

Laboratory Methods

Blood samples were processed, stored, and shipped by each institution's local Sample Processing Core to Battelle (Columbus, OH). Hemagglutinin inhibition (HAI) testing was performed in duplicate against the influenza vaccine strains in the 2009-2010 Northern Hemisphere influenza vaccine. Although there is debate about the best correlate of protection for influenza,4 seroprotection was defined as an HAI titer of ≥40 since it is the correlate recognized by the United States Food and Drug Administration.5 Seroconversion was measured at S2 and defined as a four-fold rise in HAI post-influenza vaccination compared to pre-vaccination or ≥40 if S1 was <10. Maintenance of antibody response was measured in participants with an S2 ≥40, and defined as an S3≥40. If duplicate HAI results were discrepant by more than two fold, a third test was performed and the minimum result was recorded.

Statistical Analysis

Multivariable logistic regression models were run for the binary outcomes seroprotection at S2 and S3 and seroconversion at S2. Age, BMI, stress, high risk medical conditions (yes/no), female gender, study site and transformed S1 titer were included in all models. Time in days from S1 to S3 was included in models with S3 related outcomes as a continuous variable. Restricted cubic splines were applied to age and BMI. All raw HAI titers were log transformed using the method outlined by Beyer,6 changing dilution titers to integers with HAI <10 coded as 0, 10 as 1, 20 as 2, 40 as 3 and so on. Interaction terms between age and high risk status, and stress or age and sex were tested and were not included based on non-significant p values of overall interaction terms. Figures were generated by predicting the probability of having a HAI titer ≥40 by logistic regression. All analyses were done using R version 2.12.2.

Type d'étude

Observationnel

Inscription (Réel)

510

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

50 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Subjects were enrolled at Vanderbilt University Medical Center and Marshfield Clinic Research Foundation during September and October 2009. Subjects were eligible for recruitment if they were ≥50 years of age and had no previous allergy or reaction to influenza vaccination.

La description

Inclusion Criteria:

  • Age >=50 years

Exclusion Criteria:

  • Prior vaccine allergy or history of guillain barre

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cohorte
  • Perspectives temporelles: Éventuel

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Maintenance of Immune Response using Hemagglutinin inhibition titers
Délai: 1 year
1 year

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 septembre 2009

Achèvement primaire (Réel)

1 juillet 2010

Achèvement de l'étude (Réel)

1 janvier 2014

Dates d'inscription aux études

Première soumission

9 mars 2015

Première soumission répondant aux critères de contrôle qualité

27 mars 2015

Première publication (Estimé)

30 mars 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Influenza Vaccine

S'abonner